Clinical trial · Interventional
Tumor Mutational Burden, Liquid Biopsy, Angiogenic Factors and DCE-MRI Perfusion in HPV-Negative Oropharyngeal Cancer
Tumor Mutational Burden, Liquid Biopsy, Angiogenic Factors and Magnetic Resonance Perfusion in Predicting Response to Chemoradiotherapy in HPV-Negative Oropharyngeal Squamous Cell Carcinoma and Disease Course After Treatment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective interventional study evaluates the predictive value of tumor mutational burden, liquid biopsy biomarkers (including circulating tumor DNA), angiogenic factors, and dynamic contrast-enhanced magnetic resonance (MR) perfusion imaging in patients with HPV-negative oropharyngeal squamous cell carcinoma treated with concurrent chemoradiotherapy. The aim is to improve prediction of treatment response and disease course after treatment, support decision-making regarding optimal therapy, and potentially reduce the number of imaging examinations required during follow-up.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oropharyngeal HPV Squamous Cell Carcinoma | — | UNRESOLVED | — |
| Oropharyngeal Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Concurrent Chemoradiotherapy | Procedure | — | UNRESOLVED |
| Dynamic Contrast-Enhanced MRI Perfusion (DCE-MRI) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Concurrent Chemoradiotherapy
- description
- Patients with HPV-negative oropharyngeal squamous cell carcinoma treated with standard concurrent chemoradiotherapy. Participants undergo additional diagnostic procedures including blood sampling for liquid biopsy biomarkers and dynamic contrast-enhanced MRI perfusion imaging for evaluation of predictive and prognostic markers.
- interventionNames
- Procedure: Concurrent Chemoradiotherapy
- Diagnostic Test: Dynamic Contrast-Enhanced MRI Perfusion (DCE-MRI)
Primary outcomes (2)
- measure
- Predictive Value of Biomarkers and DCE-MRI for Response to Chemoradiotherapy
- timeFrame
- Up to 6 months after completion of concurrent chemoradiotherapy
- measure
- Predictive Value of Biomarkers and DCE-MRI for Response to Chemoradiotherapy
- timeFrame
- Up to 6 months after completion of concurrent chemoradiotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed HPV-negative oropharyngeal squamous cell carcinoma * Planned treatment with concurrent chemoradiotherapy * Ability to undergo MRI examination * Signed informed consent Exclusion Criteria: * HPV-positive oropharyngeal carcinoma * Contraindications for MRI * Severe comorbidities preventing chemoradiotherapy * Pregnancy or breastfeeding * Inability to comply with study procedures
References
Publications (0)
Data not yet available